Sep 2026· Journal of Alzheimer's Disease· Vol 114, pp. 87 - 91· 0 citations· 46 references
Medicine
Abstract
An expanding body of evidence suggests that thyroid dysfunction may be clinically relevant in Alzheimer's disease (AD), although the significance of this association remains unsettled. Rather than reflecting a single biological pathway, thyroid hormone alterations in AD may involve downstream systemic adaptations related to inflammation and frailty, central dysregulation of thyroid hormone bioavailability and signaling, and upstream vulnerability mechanisms. Clarifying how these pathways intersect with cognitive and functional decline may help refine the biological interpretation of clinical heterogeneity in patients with AD.
Traditional dementia research often isolates single aspects, biomarkers or symptoms, overlooking complex interactions shaping disease risk and progression. Lysosomal and mitochondrial dysfunction, reflecting systemic processes, may explain links between Alzheimer’s and metabolic, inflammatory, cardiovascular, ageing, g...
P. Barnaghi, Antigone Fogel, C. Walsh et al.· Communications Medicine· 0 citations
Despite decades of intensive research, progress in treating late-onset Alzheimer's disease remains limited. A central problem may be conceptual: Alzheimer's disease may not be a single disease, but a heterogeneous syndrome arising from differing combinations of aging, genetic susceptibility, vascular injury, metabolic...
A. Korczyn· Journal of Alzheimer's Disea...· 0 citations
The findings support the hypothesis that neuropsychiatric symptoms could represent the early manifestation of Alzheimer's disease in older adults, and suggest depression and other neuropsychiatric symptoms may be predictors of AD's progression during its "preclinical" phase.
Alzheimer’s disease (AD) is the leading cause of dementia and a heterogeneous neurodegenerative disorder characterized by amyloid-β (Aβ) and tau pathology, impaired proteostasis, neurovascular dysfunction, maladaptive glial and immune responses, and synaptic dysfunction. Human genetic evidence supports an upstream role...
We are in an era in which increasing numbers of potentially disease-modifying treatments for Parkinson's disease are being tested in clinical development. Current definitions of disease modification have inherent limitations; hence there is a need to establish a clear, unified definition. This unified definition of dis...
A. Antonini, Robert E. Gross, María Lucia De León et al.· Journal of Parkinson's Disea...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
